42 results match your criteria suzanne miyamoto


Leadership Development Activities and Benefits From the Robert Wood Johnson Executive Nurse Fellows Program.

J Contin Educ Nurs 2021 Jul 1;52(7):344-348. Epub 2021 Jul 1.

The Robert Wood Johnson Foundation Executive Nurse Fellows (RJWF-ENF) program was the gold standard for executive career development of nurse leaders from 1997 to 2017. With more than two decades of experience, ENF program leaders encouraged the fellows to "trust the process" during the difficult times of leadership development and value the collegial relationships they could develop with other nurse fellows. This article describes the benefits of the Action Learning Model for leadership development through the experience of the Boom-X-2K action learning team from the RWJF-ENF final cohort of 2014-2017. Read More

View Article and Full-Text PDF

Emerging roles for research intensive PhD prepared nurses: Beyond faculty positions.

J Prof Nurs 2021 Jan-Feb;37(1):235-240. Epub 2020 Sep 2.

Massachusetts General Hospital, Institute of Health Professionals, 36 1st Avenue, Boston, MA 02129-4557, United States of America.

Research-intensive PhD programs need to prepare nurse scientists to bridge the chasms between research, and practice and policy in an increasingly complex healthcare system. In practice, nurse scientists are critical to building capacity for research, promoting excellence in patient-centered care, and achieving or exceeding national quality benchmarks. Moreover, they provide methodological expertise and insight to address pressing clinical questions. Read More

View Article and Full-Text PDF

The procurement of the UN sustainable development goals and the American national policy agenda of nurses.

Nurs Outlook 2019 Nov - Dec;67(6):658-663. Epub 2019 Oct 22.

American Academy of Nursing, Washington, DC.

Nurses are positioned to advance the Social Development Goals (SDGs) of the United Nations, especially Goal Three: Good Health and Well-Being. However, to do this there must be micro- and macro-level support from the profession. When the individual will of nurses is coupled with collaborative efforts of professional nursing organizations, such as the Nursing Community Coalition, policies supporting the SDGs are able to move forward. Read More

View Article and Full-Text PDF
January 2020

Development of the Leadership Influence Self-Assessment (LISA©) instrument.

Nurs Outlook 2018 Mar - Apr;66(2):130-137. Epub 2017 Nov 15.

ITS Research Services, Boston College, Chestnut Hill, MA.

Purpose: This study aims to describe the development and psychometric evaluation of the Leadership Influence Self-Assessment (LISA©) tool.

Background: LISA© was designed to help nurse leaders assess and enhance their influence capacity by measuring influence traits and practices and identifying areas of strength and weakness.

Methods: Concepts identified in the Adams Influence Model and input from content experts guided the development of 145 items for testing. Read More

View Article and Full-Text PDF
February 2019

Multiple Reaction Monitoring for the Quantitation of Serum Protein Glycosylation Profiles: Application to Ovarian Cancer.

J Proteome Res 2018 01 19;17(1):222-233. Epub 2017 Dec 19.

Department of Chemistry, University of California , Davis, California 95616, United States.

Protein glycosylation fingerprints are widely recognized as potential markers for disease states, and indeed differential glycosylation has been identified in multiple types of autoimmune diseases and several types of cancer. However, releasing the glycans leave the glycoproteins unknown; therefore, there exists a need for high-throughput methods that allow quantification of site- and protein-specific glycosylation patterns from complex biological mixtures. In this study, a targeted multiple reaction monitoring (MRM)-based method for the protein- and site-specific quantitation involving serum proteins immunoglobulins A, G and M, alpha-1-antitrypsin, transferrin, alpha-2-macroglobulin, haptoglobin, alpha-1-acid glycoprotein and complement C3 was developed. Read More

View Article and Full-Text PDF
January 2018

Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma.

Carcinogenesis 2017 03 3;38(3):271-280. Epub 2017 Jan 3.

Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis Medical Center, Sacramento, California

Lung cancer is the leading cause of cancer mortality in the United States with non-small cell lung cancer (NSCLC) adenocarcinoma being the most common histological type. Early perturbations in cellular metabolism are a hallmark of cancer, but the extent of these changes in early stage lung adenocarcinoma remains largely unknown. In the current study, an integrated metabolomics and proteomics approach was utilized to characterize the biochemical and molecular alterations between malignant and matched control tissue from 27 subjects diagnosed with early stage lung adenocarcinoma. Read More

View Article and Full-Text PDF

Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival.

Clin Proteomics 2016 27;13:31. Epub 2016 Oct 27.

Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis Medical Center, 4501 X Street, Suite 3016, Sacramento, CA 95817 USA.

Background: Lung cancer is the leading cause of cancer mortality in the United States. Non-small cell lung cancer accounts for 85% of all lung cancers for which adenocarcinoma is the most common histological type. Management of lung cancer is hindered by high false-positive rates due to difficulty resolving between benign and malignant tumors. Read More

View Article and Full-Text PDF
October 2016

Glycoproteomic Analysis of Malignant Ovarian Cancer Ascites Fluid Identifies Unusual Glycopeptides.

J Proteome Res 2016 09 23;15(9):3358-76. Epub 2016 Aug 23.

Division of Gynecologic Oncology, UC Davis Medical Center , Sacramento, California 95817, United States.

Ovarian cancer is a major cause of cancer mortality among women, largely due to late diagnosis of advanced metastatic disease. More extensive molecular analysis of metastatic ovarian cancer is needed to identify post-translational modifications of proteins, especially glycosylation that is particularly associated with metastatic disease to better understand the metastatic process and identify potential therapeutic targets. Glycoproteins in ascites fluid were enriched by affinity binding to lectins (ConA or WGA) and other affinity matrices. Read More

View Article and Full-Text PDF
September 2016

Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer.

Cancer Biomark 2016 Mar;16(4):609-17

Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis Medical Center, Sacramento, CA, USA.

Background: Recent computed tomography (CT) screening trials showed that it is effective for early detection of lung cancer, but were plagued by high false positive rates. Additional blood biomarker tests designed to complement CT screening and reduce false positive rates are highly desirable.

Objective: Identify blood-based metabolite biomarkers for diagnosing lung cancer. Read More

View Article and Full-Text PDF

Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer.

Cancer Prev Res (Phila) 2016 Apr 26;9(4):317-23. Epub 2016 Jan 26.

Department of Clinical Cancer Prevention - Research, Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.

Previous studies have suggested occurrence of altered serum glycan profiles in patients with lung cancer. Here, we aimed to determine the predictive value of serum glycans to distinguish non-small cell lung cancer (NSCLC) cases from controls in prediagnostic samples using a previously validated predictive protein marker pro-SFTPB, as anchor. Blinded prediagnostic serum samples were obtained from the Carotene and Retinol Efficacy Trial (CARET), and included a discovery set of 100 NSCLC cases and 199 healthy controls. Read More

View Article and Full-Text PDF

Protein-Specific Differential Glycosylation of Immunoglobulins in Serum of Ovarian Cancer Patients.

J Proteome Res 2016 Mar 24;15(3):1002-10. Epub 2016 Feb 24.

University of California Davis Medical Center , Sacramento, California 95817, United States.

Previous studies indicated that glycans in serum may serve as biomarkers for diagnosis of ovarian cancer; however, it was unclear to which proteins these glycans belong. We hypothesize that protein-specific glycosylation profiles of the glycans may be more informative of ovarian cancer and can provide insight into biological mechanisms underlying glycan aberration in serum of diseased individuals. Serum samples from women diagnosed with epithelial ovarian cancer (EOC, n = 84) and matched healthy controls (n = 84) were obtained from the Gynecologic Oncology Group. Read More

View Article and Full-Text PDF

Differential N-Glycosylation Patterns in Lung Adenocarcinoma Tissue.

J Proteome Res 2015 Nov 30;14(11):4538-49. Epub 2015 Sep 30.

Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center , Sacramento, California 95817, United States.

To decrease the mortality of lung cancer, better screening and diagnostic tools as well as treatment options are needed. Protein glycosylation is one of the major post-translational modifications that is altered in cancer, but it is not exactly clear which glycan structures are affected. A better understanding of the glycan structures that are differentially regulated in lung tumor tissue is highly desirable and will allow us to gain greater insight into the underlying biological mechanisms of aberrant glycosylation in lung cancer. Read More

View Article and Full-Text PDF
November 2015

The Influence of Emerging Nursing Strategy and Policy Leaders: An Interview With Dr Suzanne Miyamoto.

J Nurs Adm 2015 Sep;45(9):420-2

Author Affiliation: Associate Director, The Center for Innovations in Care Delivery and Connell Nursing Research Scholar, Massachusetts General Hospital, Boston.The author declares no conflicts of interest.

This department highlights emerging nursing leaders who have demonstrated great potential in advancing innovation and patient care leadership in practice, policy, research, education, and theory. This interview profiles Suzanne Miyamoto, PhD, RN, Senior Director of Government Affairs and Health Policy at the American Association of Colleges of Nursing. Read More

View Article and Full-Text PDF
September 2015

Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.

J Clin Oncol 2015 Nov 17;33(33):3880-6. Epub 2015 Aug 17.

William R. Wikoff, Brian DeFelice, and Oliver Fiehn, National Institutes of Health West Coast Metabolomics Center, University of California, Davis, Davis; Suzanne Miyamoto and David Gandara, University of California, Davis, Davis Comprehensive Cancer Center, Sacramento, CA; Samir Hanash, Yang Zhao, Ziding Feng, and Ayumu Taguchi, The University of Texas MD Anderson Cancer Center, Houston, TX; and Matt Barnett and Gary Goodman, Fred Hutchison Cancer Research Center, Seattle, WA.

Purpose: We have investigated the potential of metabolomics to discover blood-based biomarkers relevant to lung cancer screening and early detection. An untargeted metabolomics approach was applied to identify biomarker candidates using prediagnostic sera from the Beta-Carotene and Retinol Efficacy Trial (CARET) study.

Patients And Methods: A liquid chromatography/mass spectrometry hydrophilic interaction method designed to profile a wide range of metabolites was applied to prediagnostic serum samples from CARET participants (current or former heavy smokers), consisting of 100 patients who subsequently developed non-small-cell lung cancer (NSCLC) and 199 matched controls. Read More

View Article and Full-Text PDF
November 2015

Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer.

Cancer Epidemiol Biomarkers Prev 2015 Nov 17;24(11):1716-23. Epub 2015 Aug 17.

Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis Medical Center, Sacramento, California.

Background: Untargeted metabolomics was used in case-control studies of adenocarcinoma (ADC) lung cancer to develop and test metabolite classifiers in serum and plasma as potential biomarkers for diagnosing lung cancer.

Methods: Serum and plasma were collected and used in two independent case-control studies (ADC1 and ADC2). Controls were frequency matched for gender, age, and smoking history. Read More

View Article and Full-Text PDF
November 2015

Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry.

Metabolites 2015 Apr 9;5(2):192-210. Epub 2015 Apr 9.

Genome Center, UC Davis, 451 Health Sciences Drive, University of California, Davis, CA 95616, USA.

Lung cancer is a leading cause of cancer deaths worldwide. Metabolic alterations in tumor cells coupled with systemic indicators of the host response to tumor development have the potential to yield blood profiles with clinical utility for diagnosis and monitoring of treatment. We report results from two separate studies using gas chromatography time-of-flight mass spectrometry (GC-TOF MS) to profile metabolites in human blood samples that significantly differ from non-small cell lung cancer (NSCLC) adenocarcinoma and other lung cancer cases. Read More

View Article and Full-Text PDF

Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma.

Cancer Prev Res (Phila) 2015 May 5;8(5):410-8. Epub 2015 Feb 5.

Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis Medical Center, Sacramento, California.

Adenocarcinoma, a type of non-small cell lung cancer, is the most frequently diagnosed lung cancer and the leading cause of lung cancer mortality in the United States. It is well documented that biochemical changes occur early in the transition from normal to cancer cells, but the extent to which these alterations affect tumorigenesis in adenocarcinoma remains largely unknown. Herein, we describe the application of mass spectrometry and multivariate statistical analysis in one of the largest biomarker research studies to date aimed at distinguishing metabolic differences between malignant and nonmalignant lung tissue. Read More

View Article and Full-Text PDF

Evaluation of glycomic profiling as a diagnostic biomarker for epithelial ovarian cancer.

Cancer Epidemiol Biomarkers Prev 2014 Apr 20;23(4):611-21. Epub 2014 Feb 20.

Authors' Affiliations: Division of Biostatistics, Department of Public Health Sciences; Department of Chemistry, University of California, Davis; UC Davis Cancer Center; and Division of Gynecologic Oncology, UC Davis Medical Center, Sacramento, California.

Background: Prior studies suggested that glycans were differentially expressed in patients with ovarian cancer and controls. We hypothesized that glycan-based biomarkers might serve as a diagnostic test for ovarian cancer and evaluated the ability of glycans to distinguish ovarian cancer cases from matched controls.

Methods: Serum samples were obtained from the tissue-banking repository of the Gynecologic Oncology Group, and included healthy female controls (n = 100), women diagnosed with low malignant potential (LMP) tumors (n = 52), and epithelial ovarian cancers (EOC) cases (n = 147). Read More

View Article and Full-Text PDF

Absolute quantitation of immunoglobulin G and its glycoforms using multiple reaction monitoring.

Anal Chem 2013 Sep 30;85(18):8585-93. Epub 2013 Aug 30.

Department of Chemistry, University of California , One Shields Avenue, Davis, California, 95616, United States.

Studies aimed toward glycan biomarker discovery have focused on glycan characterization by the global profiling of released glycans. Site-specific glycosylation analysis is less developed but may provide new types of biomarkers with higher sensitivity and specificity. Quantitation of peptide-conjugated glycans directly facilitates the differential analysis of distinct glycoforms associated with specific proteins at distinct sites. Read More

View Article and Full-Text PDF
September 2013

Enrichment strategies in glycomics-based lung cancer biomarker development.

Proteomics Clin Appl 2013 Oct 6;7(9-10):664-76. Epub 2013 Aug 6.

Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.

Purpose: There is a need to identify better glycan biomarkers for diagnosis, early detection, and treatment monitoring in lung cancer using biofluids such as blood. Biofluids are complex mixtures of proteins dominated by a few high abundance proteins that may not have specificity for lung cancer. Therefore, two methods for protein enrichment were evaluated; affinity capturing of IgG and enrichment of medium abundance proteins, thus allowing us to determine which method yields the best candidate glycan biomarkers for lung cancer. Read More

View Article and Full-Text PDF
October 2013

Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses.

Anal Bioanal Chem 2013 May 23;405(14):4953-8. Epub 2013 Mar 23.

Department of Chemistry, University of California Davis, Davis, CA 95616, USA.

Many studies focused on the discovery of novel biomarkers for the diagnosis and treatment of disease states are facilitated by mass spectrometry-based technology. HPLC coupled to mass spectrometry is widely used; miniaturization of this technique using nano-liquid chromatography (LC)-mass spectrometry (MS) usually results in better sensitivity, but is associated with limited repeatability. The recent introduction of chip-based technology has significantly improved the stability of nano-LC-MS, but no substantial studies to verify this have been performed. Read More

View Article and Full-Text PDF

Isomer-specific chromatographic profiling yields highly sensitive and specific potential N-glycan biomarkers for epithelial ovarian cancer.

J Chromatogr A 2013 Mar 11;1279:58-67. Epub 2013 Jan 11.

Department of Chemistry, University of California, Davis, CA, USA.

Aberrant glycosylation has been observed for decades in essentially all types of cancer, and is now well established as an indicator of carcinogenesis. Mining the glycome for biomarkers, however, requires analytical methods that can rapidly separate, identify, and quantify isomeric glycans. We have developed a rapid-throughput method for chromatographic glycan profiling using microfluidic chip-based nanoflow liquid chromatography (nano-LC)/mass spectrometry. Read More

View Article and Full-Text PDF

Developments in the identification of glycan biomarkers for the detection of cancer.

Mol Cell Proteomics 2013 Apr 30;12(4):846-55. Epub 2013 Jan 30.

Department of Chemistry, University of California Davis, Davis, California 95616, USA.

Changes in glycosylation readily occur in cancer and other disease states. Thanks to recent advances in the development of analytical techniques and instrumentation, especially in mass spectrometry, it is now possible to identify blood-derived glycan-based biomarkers using glycomics strategies. This review is an overview of the developments made in the search for glycan-based cancer biomarkers and the technologies currently in use. Read More

View Article and Full-Text PDF

The glycolyzer: automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery.

Proteomics 2012 Aug;12(15-16):2523-38

Department of Chemistry, University of California, Davis, CA, USA.

Human serum glycomics is a promising method for finding cancer biomarkers but often lacks the tools for streamlined data analysis. The Glycolyzer software incorporates a suite of analytic tools capable of identifying informative glycan peaks out of raw mass spectrometry data. As a demonstration of its utility, the program was used to identify putative biomarkers for epithelial ovarian cancer from a human serum sample set. Read More

View Article and Full-Text PDF

N-Glycan profiling of dried blood spots.

Anal Chem 2012 Jan 19;84(1):396-402. Epub 2011 Dec 19.

Department of Chemistry, University of California-Davis, One Shields Avenue, Davis, California 95616, USA.

Serum N-glycan profiles for use as clinical biomarkers of disease(s) is of increasing scientific interest. Promising profiles have already been identified in several diseases, including cancer, Alzheimer's, and diabetes. Venipuncture is routinely performed to collect the blood necessary for this type of analysis, but blood from a fingerstick placed on filter paper (known as dried blood spots (DBS)) is more advantageous. Read More

View Article and Full-Text PDF
January 2012

High-mannose glycans are elevated during breast cancer progression.

Mol Cell Proteomics 2011 Jan 19;10(1):M110.002717. Epub 2010 Nov 19.

Department of Chemistry, University of California Davis, Davis, CA 95616, USA.

Alteration in glycosylation has been observed in cancer. However, monitoring glycosylation changes during breast cancer progression is difficult in humans. In this study, we used a well-characterized transplantable breast tumor mouse model, the mouse mammary tumor virus-polyoma middle T antigen, to observe early changes in glycosylation. Read More

View Article and Full-Text PDF
January 2011

Human serum processing and analysis methods for rapid and reproducible N-glycan mass profiling.

J Proteome Res 2010 Oct;9(10):4952-9

Department of Chemistry, University of California Davis, Davis, California 95616, USA.

Glycans constitute a new class of compounds for biomarker discovery. Glycosylation is a common post-translational modification and is often associated with transformation to malignancy. To analyze glycans, they are released from proteins, enriched, and measured with mass spectrometry. Read More

View Article and Full-Text PDF
October 2010

The development of retrosynthetic glycan libraries to profile and classify the human serum N-linked glycome.

Proteomics 2009 Jun;9(11):2986-94

Department of Chemistry, University of California Davis, Davis, CA 95616, USA.

Annotation of the human serum N-linked glycome is a formidable challenge but is necessary for disease marker discovery. A new theoretical glycan library was constructed and proposed to provide all possible glycan compositions in serum. It was developed based on established glycobiology and retrosynthetic state-transition networks. Read More

View Article and Full-Text PDF

Profile of native N-linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time-of-flight mass spectrometry.

Proteomics 2009 Apr;9(7):1939-51

Department of Chemistry, University of California at Davis, Davis, CA 95616, USA.

Protein glycosylation involves the addition of monosaccharides in a stepwise process requiring no glycan template. Therefore, identifying the numerous glycoforms, including isomers, can help elucidate the biological function(s) of particular glycans. A method to assess the diversity of the N-linked oligosaccharides released from human serum without derivatization has been developed using on-line nanoLC and high resolution TOF MS. Read More

View Article and Full-Text PDF